Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Scientific Reports|July 26, 2013
Novel insights into breast cancer genetic variance through RNA sequencingAnelia Horvath, Suresh Babu Pakala, Prakriti Mudvari, et al.
Cancer Research|February 28, 2016
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient SurvivalPetra den Hollander, Kathryn Rawls, Anna Tsimelzon, et al.
Molecular and Cellular Biology|April 25, 2002
Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression functionMaofu Fu, Chenguang Wang, Jian Wang, et al.
Breast Cancer Research and Treatment|June 18, 2009
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cellsFrancesca De Amicis, Janagi Thirugnansampanthan, Yukun Cui, et al.
Nucleic Acids Research|January 14, 2020
Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activityFabio Stossi, Radhika D Dandekar, Maureen G Mancini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2014
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancerMatthew D Burstein, Anna Tsimelzon, Graham M Poage, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2011
Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cellsJennifer Selever, Guowei Gu, Michael T Lewis, et al.
Cell Communication and Signaling : CCS|November 15, 2024
Evidence that CRISPR-Cas9 Y537S-mutant expressing breast cancer cells activate Yes-associated protein 1 to driving the conversion of normal fibroblasts into cancer-associated fibroblastsLuca Gelsomino, Amanda Caruso, Emine Tasan, et al.
British Journal of Cancer|December 1, 2020
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancerDerek Dustin, Guowei Gu, Amanda R Beyer, et al.
Cancer Research|January 7, 2026
Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast CancerSarah K Herzog, Jessica H Stevens, Guowei Gu, et al.
Pageof 7